- Business Wire•1 hour agoTwo New Trials of Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016
Merck , known as MSD outside the United States and Canada, today announced that extensive data on KEYTRUDA® , the company’s anti-PD-1 therapy, have been accepted for presentation at the European Society for Medical Oncology 2016 Congress in Copenhagen, Denmark, Oct.
- Market Realist•yesterday
Mylan's commercial developments include the acquisition of Renaissance Acquisition Holdings' tropicals business and the acquisition of Meda Aktiebolag.
Merck & Co., Inc. (MRK.BA)
Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
|Day's Range||95.65 - 95.65|
|52wk Range||71.00 - 95.65|
|1y Target Est||N/A|
|P/E Ratio (ttm)||52.47|
|Avg Vol (3m)||1,166|
|Dividend & Yield||N/A (N/A)|